Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Sorry, there are no financial reports available yet.
Investor presentations
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Investor Presentation Conference Call 6th July, 2020
Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020
JP Morgan Healthcare Conference, San Francisco, 15th January 2020
Linzagolix Phase 3 PRIMROSE 2 Trial Results
Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
Cantor Global Healthcare Conference October 4 2019
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Press Releases
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
press release
December 5, 2017
OBE022 is a first-in-class, oral and selective PGF2alpha receptor antagonist for the potential treatment of preterm labor to delay or…
Read moreObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
press release
November 14, 2017
– All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months – Geneva, Switzerland and Boston, MA – November 14,…
Read moreObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis
press release
November 7, 2017
Geneva, Switzerland and Boston, MA – November 7, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2019
May 8, 2019
ObsEva Annual General Meeting 2018
May 9, 2018
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
